Natco Pharma slips as Chennai plant shuts operations due to flooding

Image
Capital Market
Last Updated : Dec 02 2015 | 2:13 PM IST

Natco Pharma fell 1.76% to Rs 515 at 13:00 IST on BSE after the company said its wholly-owned subsidiary's active pharmaceuticals ingredient plant operations at Chennai are temporarily suspended due to flooding.

The announcement was made during trading hours today, 2 December 2015.

Meanwhile, the BSE Sensex was down 93.88 points, or 0.36%, to 26,075.53.

On BSE, so far 31,000 shares were traded in the counter, compared with an average volume of 13,684 shares in the past one quarter.

The stock hit a high of Rs 534.20 and a low of Rs 508.05 so far during the day. The stock hit a record high of Rs 598 on 26 November 2015. The stock hit a 52-week low of Rs 260.38 on 17 December 2014.

The stock had outperformed the market over the past one month till 1 December 2015, rising 2.13% compared with 1.83% decline in the Sensex. The scrip had also outperformed the market in past one quarter, rising 16.25% as against Sensex's 1.84% decline.

The mid-cap company has an equity capital of Rs 34.83 crore. Face value per share is Rs 2.

Natco Pharma stated that its wholly-owned subsidiary's active pharmaceuticals ingredient (API) plant at Manali Industrial Area in Chennai has temporarily suspended operations due to flooding caused by incessant rains in the plant area.

The unit manufactures a few oncology related APIs at its Manali site. The company believes that this temporary shutdown should not impact/impair its pipeline launches associated with this plant. The unit is also adequately insured for any losses it has incurred in fixed assets, raw materials and loss in production including work-in-progress. Actual losses will be assessed once this natural calamity passes by, and the plant is back in full operational mode, the company added.

On a consolidated basis, net profit of Natco Pharma declined 8.6% to Rs 29.57 crore on 7.8% rise in net sales to Rs 229.18 crore in Q2 September 2015 over Q2 September 2014.

Natco Pharma manufactures generic dosage forms, bulk actives and intermediates for the Indian and international markets.

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 02 2015 | 1:03 PM IST

Next Story